

NOTIFICATION OF DATE OF 2025 ANNUAL GENERAL MEETING

MELBOURNE, Australia, 19 September 2025: Dimerix Limited (ASX: DXB) a biopharmaceutical company with a Phase 3 clinical asset in inflammatory disease, advises that the Company's Annual General Meeting (AGM) will be held on 18 November 2025 at 3:30pm AEDT at Dimerix Limited's office at 425 Smith Street, Fitzroy VIC 3065.

Further to Listing Rule 3.13.1, the Company advises that the closing date for director nominations is 30 September 2025.

Following formalities, Dimerix's CEO and Managing Director, Dr Nina Webster will provide an update to shareholders.

In order to receive electronic communications, shareholders are encouraged to contact the share registry, Automic Group, via the details below:

- Visit: www.automicgroup.com.au
- Email: hello@automic.com.au
- Telephone: (Within Australia) 1300 288 664 (Outside Australia) +61 2 9698 5414

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster	Jane Lowe
Dimerix Limited	IR Department
Chief Executive Officer & Managing Director	Tel: +61 411 117 774
Tel: +61 1300 813 321	E: jane.lowe@irdepartment.com.au
E: investor@dimerix.com	

Follow us on [LinkedIn](#) and [X](#)

Authorised for lodgement by the Board of the Company

—END—



About Dimerix Limited

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including kidney diseases. Dimerix is currently focused on developing its proprietary Phase 3 product candidate DMX-200, for Focal Segmental Glomerulosclerosis (FSGS) kidney disease, and is also developing DMX-700 for respiratory disease. DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. For more information, please visit the company's website at www.dimerix.com.

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs.

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. info@dimerix.com

For personal use only